This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis Of The Leading Generic Players In 2013

NEW YORK, April 11, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013


"PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013" applies GlobalData's proprietary ranking methodology to compare the competitive position of 30 generic pharmaceutical companies across various markets on 12 financial metrics. The performances of these companies are analyzed based on financial performance, cost-containment, capital structure, and efficiency to illustrate the different strategies these companies are using to increase shareholder value and capture market share from branded pharmaceuticals manufacturers. In addition to the financial metrics, this report presents SWOT analyses of the major players, and describes the operations strategy of these companies.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.


- The report provides analysis of the key drivers and trends shaping the global generics industry.- The report identifies the key generic players in various markets, including a special focus on emerging markets such as India, China, Russia, and Brazil. - Furthermore, it provides detailed analysis of the various generic markets including the US, Europe, APAC, and BRIC.- The report contains expert insights on the corporate strategies of generic companies seeking competitive advantage in the highly competitive generics industry.

Reasons to buy

- Benchmark your company's performance against other generic pharmaceutical companies to identify strengths that can be leveraged and/or areas of possible improvement- Analyze and track the strategies that successful generic pharmaceutical companies are using to gain share in the increasingly competitive market- Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending, asset structure, and efficiency- Use this information as an independent source for your due diligence and transaction strategy

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,756.97 -41.52 -0.23%
S&P 500 2,085.41 -4.70 -0.22%
NASDAQ 5,104.4380 -23.0870 -0.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs